Bone Regeneration FranchiseTegenix FDA Review ProgressTetratherix Limited 2026Anchored by ScienceASX Release6 October 2026ASX:TTXTetratherix Limited (ASX: TTX) advises that it has received a substantive review update from the US Foodand Drug Administration (FDA) on its 510(k) submission for...
Tegenix FDA Review Progress
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Tetratherix
- Notification regarding unquoted securities - TTX
- Line of sight ophthalmic tissue spacing US revenue
- Tetratherix Ships First US Polymer, Revenue Begins
- Application for quotation of securities - TTX
- Results Presentation 2026
Later from Tetratherix
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - TTX
- TegenEOS Biologic Pathway
- Quarterly Activities/Appendix 4C Cash Flow Report
- Details of Auditor Appointment/Resignation
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix